In these models, fluorescence-tagged and oncogenic-engineered cancerous precursors were generated in vitro and then transplanted into immune-compromised mice to generate acute leukemia (Fig. 1) . The mice then underwent cycles of fasting during leukemogenesis. Notably, the authors found that early fasting was sufficient to prevent the initiation, and to almost completely prevent the development, of both B cell and T cell ALLs. Fasting not only had a strong inhibitory impact on the early growth of ALLs, but was also quite effective at reducing leukemia progression at later stages associated with high disease burden. This finding raises the possibility that fasting or its pharmacological mimetics might have a role in treating patients who have advanced leukemia. Interestingly, the effects of fasting were found to be cancer-type dependent; in contrast to ALL, fasting cycles had negligible effects on AML (Fig. 1) .
In response to fasting, ALL cells demonstrated rapid proliferation, apoptosis and differentiation. To gain more mechanistic insight into how fasting might eliminate ALL cells, the authors carried out RNA sequencing and pathway analysis and found a prominent signature indicative of LEPR signaling in these cells, including strong activation of PRDM1. PRDM1 is a downstream target of LEPR-mediated STAT signaling that drives protein and its downstream effector PR-domain zinc-finger protein 1 (PRDM1).
Similar to normal hematopoiesis, leukemia often follows a hierarchy whereby primitive, self-renewing, leukemia-propagating cells give rise to bulk leukemic blast cells 1 . Unlike normal hematopoietic cells, leukemic blast cells are blocked at an early stage of their development and fail to differentiate into mature, functional hematopoietic cells. In acute leukemia, neoplastic progenitors proliferate and overrun normal hematopoietic cells of the marrow, spleen and peripheral blood, and eventually, they reduce blood cell counts. Accordingly, therapeutic strategies that force cancer cells to resume the process of lineage maturation have been proposed as an alternative approach to cytotoxic chemotherapy for eliminating cancer cells such as leukemia. However, despite the success of all-trans-retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL), which enables the differentiation of APL leukemic blast cells, only a limited number of pharmacological agents that drive the terminal differentiation of leukemic cells have been identified 4 . Lu et al. 2 turned their attention to dietary approaches for inducing the differentiation of leukemia cells. The authors first investigated the effects of fasting on ALL and AML development by using mouse models of acute leukemia. Clearly, the contribution of different suPAR forms, their glycosylation and splice variations will require further study. The identification and measurement of pathological suPAR forms will carry prognostic significance.
Undoubtedly, the authors' study will encourage us to consider extrarenal origins of kidney disease, which might be attractive therapeutic targets for these patients.
from the xenograft mouse model strongly support the notion that suPAR-associated glomerular dysfunction might be the result of a primary hematopoietic stem cell disorder. These findings could open up novel therapeutic approaches for suPAR-mediated renal diseases and contribute to the understanding of myeloid cell function, inflammation and kidney disease.
In the clinic, these results suggest that stem cell or bone marrow transplants might be considered to prevent post-transplantation recurrence of FSGS, or even as treatment for the original disease. Additional therapeutic considerations might include targeting suPAR levels or interfering with suPAR-β 3 -integrin signaling. One might ask what the effects of corticosteroids are on the bone marrow-derived cells. Given the lack of human homologs for Gr-1 or Sca-1, the equivalent cell subset in humans responsible for pathogenic suPAR remains to be determined. Furthermore, the precise role of patient-derived CD34 + HSPCs on kidneydisease progression remains to be addressed.
The authors did try to identify the precise contribution of different suPAR forms to certain types of renal disease, and they generated novel transgenic mice expressing suPAR in fat tissue to test the effect of chronic full-length suPAR on kidney function. These suPARtransgenic mice showed much higher levels of plasma suPAR, but lesser degrees of proteinuria, as compared to the suPAR-associated proteinuric animals that they studied. Because suPAR can be present in multiple forms, it is possible that suPAR generated from animal models of proteinuria might be qualitatively different from full-length suPAR, or that suPAR can act as a mixture of different forms.
Starving leukemia to induce differentiation
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A new study shows that fasting induces the differentiation and elimination of some types of leukemia in mice, which implicates fasting or its mimetics as a novel strategy for the treatment of this disease. Acute leukemias, characterized by the excess production of hematopoietic progenitor cells of the lymphoid (acute lymphoblastic leukemia, ALL) or myeloid lineages (acute myeloid leukemia, AML), are among the most common causes of childhood cancer worldwide. Both ALL and AML are challenging to treat because subsets of patients fail to respond to conventional therapies, such as chemotherapy or radiation, as well as to targeted therapies, such as tyrosine-kinase inhibitors and bone marrow transplantation 1 . In this issue of Nature Medicine, Lu et al. 2 explore the therapeutic potential of fasting (i.e., food deprivation without water restriction), a dietary intervention that has been previously proposed to promote normal hematopoietic regeneration 3 , as a treatment for acute leukemia. Their findings reveal that periodic fasting selectively inhibits the development of ALL, but not AML, by upregulating the leptin receptor (LEPR)owing to the development of leptin resistance, which is associated with high levels of leptin, low levels of LEPR and diminished sensitivity to the hormone 8 . It was then proposed that the reversal of leptin resistance might improve the treatment of obesity. Notably, as reported by Lu et al. 2 , fasting reduces leptin levels while boosting LEPR signaling in ALL (i.e., it enhances leptin sensitivity). The use of leptin sensitizers, such as withaferin A or metaformin, might represent an effective alternative for mimicking the antitumor effects of fasting in the treatment of ALL 9 . However, just as AML and ALL have different requirements for LEPR signaling in their maintenance, such differences might also exist across other tissues, cell lineages or even between normal and cancerous cells; therefore, it will be important to decipher the potential toxicities of fasting or of LEPR-based therapies.
Recent studies indicate that in response to therapy, a subset of acute leukemias can switch lineages or acquire mixed lineage phenotypes (i.e., they possess both myeloid and lymphoid features) at relapse, which might permit such leukemias to escape fasting-or LEPR-induced differentiation 10 . Thus, proposed therapeutic interventions will need to overcome such complications or mechanisms of escape. Despite these potential challenges, this study identifies an important role for LEPR and PRDM1 signaling in leukemic cell differentiation that might one day be exploited therapeutically to reduce disease burden for patients with ALL.
to chemotherapy 6 . Furthermore, recent studies focused on the hematopoietic and immune systems illustrate that fasting or fasting mimetics enhance antitumor immunity, which results in delayed progression of breast cancer and melanoma in preclinical models 7 . However, whether these findings apply to humans is unknown.
As an alternative to dietary interventions, another approach might be to co-opt pathways activated by such interventions with pharmacologic agents. In this study, Lu et al. 2 show that in patients with pediatric pre-B-ALL, LEPR signaling is highly associated with the prognosis of the disease. Fasting-induced LEPR signaling, for instance, effectively inhibits human B-ALL disease development in xenograft assays. Additionally, overexpression of LEPR or its effector PRDM1 in mouse models of ALL recapitulated the ability of fasting to promote the differentiation of ALL cells. Collectively, these results suggest that fasting-induced LEPR and PRDM1 signaling can be exploited therapeutically for the treatment of ALL.
Leptin, a hormone known for its role in satiety, held hope as a treatment for obesity; however, treatments involving leptin failed in part the terminal differentiation of lymphoid progenitors. The authors propose that fasting upregulates the expression of LEPR and its downstream transcription factor PRDM1, and that this process enables ALL blast cells to differentiate (Fig. 1) . The authors reveal that LEPR expression was reduced upon the development of ALL but not that of AML as compared to its expression prior to disease development. Furthermore, they show that attenuation of LEPR signaling is essential for the maintenance of ALL, but not of AML, in two mouse models of obesity, which indicates that the activation of LEPR signaling underlies the fasting-induced inhibition of ALL growth. Although it remains unclear whether fasting universally inhibits the development of most ALLs-even those with different genetic drivers from those tested in these mouse modelsthe authors provide convincing evidence that fasting-induced LEPR signaling might mitigate disease burden in some types of ALL.
Dietary interventions have been applied successfully to treat certain solid cancers in animal models 5 . For example, periodic fasting sensitizes a wide range of xenograft tumor models, such as melanoma, glioma and breast cancer, Figure 1 Fasting regulates LEPR-mediated leukemia differentiation. Fluorescence-tagged preleukemic acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) cells are transplanted into recipient mice. As leukemia develops in the mice, ALL cells express low levels of LEPR. However, Lu et al. 2 show that fasting induces LEPR expression, which leads to the activation of its downstream effector PRDM1. At early stages, this fasting-induced gene-expression program prevents the development of leukemia, and at later stages, it drives the differentiation and eventual depletion of leukemic cells. By contrast, AML cells express high levels of LEPR and are refractory to the effects of fasting. 
